Chris Stevens is the Chief Operating Officer (COO) of Rocket Pharma, responsible for shaping corporate strategy, scaling operations, and driving business growth. As COO, Chris leads the Technical Development, Technical Operations, Quality, and Program & Portfolio Management functions.
Chris is a seasoned executive with 25 years of experience across technical operations, product strategy, and general management. Prior to Rocket, Chris most recently served as Executive Vice President and Chief Patient Supply Officer at Spark Therapeutics, where he successfully led teams across manufacturing, supply chain, quality, compliance, engineering, EHS, and facilities, playing a key role in delivering gene therapies to patients globally.
During his tenure at Spark, he was also Head of Manufacturing through the approval and launch of Luxturna, the first gene therapy approved for a genetic disease in the U.S. and EU. He later served as Asset General Manager for the Hemophilia A program and subsequently Head of Product Strategy, overseeing program development for Spark’s entire portfolio.
Prior to Spark, Chris led teams at GlaxoSmithKline focused on strategy, operations, and planning, as well as GMP clinical manufacturing operations including process transfer and cell banking. Earlier in his career he held roles of increasing responsibility at Bristol-Myers Squibb in process engineering, manufacturing and supply chain in Massachusetts, Indiana and Puerto Rico.
Chris received his M.S. in Industrial Management from the University of Southern Indiana and a B.S. in Chemical Engineering from Purdue University.
What is Christopher James Stevens' net worth?
The estimated net worth of Christopher James Stevens is at least $1.78 million as of August 11th, 2026. Mr. Stevens owns 505,784 shares of Rocket Pharmaceuticals stock worth more than $1,782,889 as of August 24th. This net worth estimate does not reflect any other assets that Mr. Stevens may own. Learn More about Christopher James Stevens' net worth.
How do I contact Christopher James Stevens?
Has Christopher James Stevens been buying or selling shares of Rocket Pharmaceuticals?
During the last quarter, Christopher James Stevens has sold $128,303.00 in Rocket Pharmaceuticals stock. Most recently, Christopher James Stevens sold 36,658 shares of the business's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $3.50, for a transaction totalling $128,303.00. Following the completion of the sale, the chief operating officer now directly owns 505,784 shares of the company's stock, valued at $1,770,244. Learn More on Christopher James Stevens' trading history.
Who are Rocket Pharmaceuticals' active insiders?
Rocket Pharmaceuticals' insider roster includes Elisabeth Bjork (Director), Sarbani Chaudhuri (Insider), Gotham Makker (Director), John Militello (Insider), Aaron Ondrey (CFO), Kinnari Patel (Insider), Jonathan Schwartz (Chief Gene Therapy Officer), Gaurav Shah (CEO), David Southwell (Director), David Southwell (Director), Christopher Stevens (Chief Operating Officer), and Martin Wilson (General Counsel & Chief Corporate Officer). Learn More on Rocket Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Rocket Pharmaceuticals?
During the last year, Rocket Pharmaceuticals insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $34,100.00. During the last year, insiders at the biotechnology company sold shares 19 times. They sold a total of 192,679 shares worth more than $663,255.61. The most recent insider tranaction occured on August, 18th when General Counsel Martin Wilson sold 631 shares worth more than $2,132.78. Insiders at Rocket Pharmaceuticals own 21.3% of the company.
Learn More about insider trades at Rocket Pharmaceuticals. Information on this page was last updated on 8/18/2026.
